This study is being done to answer the following question: By adding an additional drug to the drug that is typically given, can we increase the time the cancer is controlled by the treatment? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your non-small cell metastatic EGFR-mutant lung cancer. The usual approach is defined as care most people get for metastatic EGFR-mutant lung cancer.
Testing the addition of bevacizumab to AZD9291 (osimertinib) as a first-treatment for patients with EGFR-mutant lung cancer that has metastasized
OPEN TO ACCRUAL